Prosthetic Heart Valve Thrombosis

Journal of the American College of Cardiology

Volumn 68, Issue 24, 2016, Pages 2670-2689

  Dangas, George D ^a   Weitz, Jeffrey I ^b   Giustino, Gennaro ^a   Makkar, Raj ^c   Mehran, Roxana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

antithrombotic therapies; valve replacement; valvular heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; HEPARIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; RIVAROXABAN; TICAGRELOR; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; CATHETER THROMBOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EMBOLISM; HEART INFARCTION; HEART VALVE BIOPROSTHESIS; HEART VALVE REPLACEMENT; HEMODYNAMICS; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; MECHANICAL HEART VALVE; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROSTHETIC VALVE DYSFUNCTION; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURGICAL APPROACH; THROMBOEMBOLISM; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VALVULAR HEART DISEASE; ADVERSE EFFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; PROSTHESIS COMPLICATION; THROMBOSIS;

ANTICOAGULANTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMANS; PROSTHESIS FAILURE; THROMBOSIS;

EID: 85003945062     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.958     Document Type: Review

References (72)

1. 1 Iung, B., Vahanian, A., Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 8 (2011), 162–172.
2. 2 Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Published correction appears in J Am Coll Cardiol 2014;63:2489]. J Am Coll Cardiol 63 (2014), e57–e185.
3. 3 Sun, J.C., Davidson, M.J., Lamy, A., et al. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 374 (2009), 565–576.
4. 4 Taramasso, M., Pozzoli, A., Latib, A., et al. New devices for TAVI: technologies and initial clinical experiences. Nat Rev Cardiol 11 (2014), 157–167.
5. 5 Roudaut, R., Serri, K., Lafitte, S., Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart 93 (2007), 137–142.
6. 6 Zoghbi, W.A., Chambers, J.B., Dumesnil, J.G., et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound. J Am Soc Echocardiogr 22 (2009), 975–1014.
7. 7 Deviri, E., Sareli, P., Wisenbaugh, T., et al. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 17 (1991), 646–650.
8. 8 Egbe, A.C., Pislaru, S.V., Pellikka, P.A., et al. Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. J Am Coll Cardiol 66 (2015), 2285–2294.
9. 9 Makkar, R.R., Fontana, G., Jilaihawi, H., et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373 (2015), 2015–2024.
10. 10 Pache, G., Schoechlin, S., Blanke, P., et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J 37 (2016), 2263–2271.
11. 11 Habets, J., Budde, R.P., Symersky, P., et al. Diagnostic evaluation of left-sided prosthetic heart valve dysfunction. Nat Rev Cardiol 8 (2011), 466–478.
12. 12 Lin, S.S., Tiong, I.Y., Asher, C.R., et al. Prediction of thrombus-related mechanical prosthetic valve dysfunction using transesophageal echocardiography. J Am Coll Cardiol 86 (2000), 1097–1101.
13. 13 Laplace, G., Lafitte, S., Labèque, J.N., et al. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. J Am Coll Cardiol 43 (2004), 1283–1290.
14. 14 Puvimanasinghe, J.P., Steyerberg, E.W., Takkenberg, J.J., et al. Prognosis after aortic valve replacement with a bioprosthesis: predictions based on meta-analysis and microsimulation. Circulation 103 (2001), 1535–1541.
15. 15 Brown, M.L., Park, S.J., Sundt, T.M., et al. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg 144 (2012), 108–111.
16. 16 Heras, M., Chesebro, J.H., Fuster, V., et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25 (1995), 1111–1119.
17. 17 Le Tourneau, T., Lim, V., Inamo, J., et al. Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study. Chest 136 (2009), 1503–1513.
18. 18 Pislaru, S.V., Hussain, I., Pellikka, P.A., et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 47 (2015), 725–732.
19. 19 Kapadia, S.R., Leon, M.B., Makkar, R.R., et al., PARTNER trial investigators. 5-Year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2485–2491.
20. 20 Mack, M.J., Leon, M.B., Smith, C.R., et al., PARTNER 1 trial investigators. 5-Year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2477–2484.
21. 21 Reardon, M.J., Adams, D.H., Kleiman, N.S., et al. 2-year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 66 (2015), 113–121.
22. 22 Latib, A., Naganuma, T., Abdel-Wahab, M., et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv, 8, 2015, e001779.
23. 23 Stortecky, S., Windecker, S., Stroke: an infrequent but devastating complication in cardiovascular interventions. Circulation 126 (2012), 2921–2924.
24. 24 Whitlock, R.P., Sun, J.C., Fremes, S.E., et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e576S–e600.
25. 25 Vahanian, A., Alfieri, O., Andreotti, F., et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33 (2012), 2451–2496.
26. 26 Leetmaa, T., Hansson, N.C., Leipsic, J., et al. Early aortic transcatheter heart valve thrombosis: diagnostic value of contrast-enhanced multidetector computed tomography. Circ Cardiovasc Interv, 8, 2015, e001596.
27. 27 Hansson, N.C., Grove, E.L., Andersen, H.R., et al. Transcatheter aortic heart valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 68 (2016), 2059–2069.
28. 28 Wolberg, A.S., Aleman, M.M., Leiderman, K., et al. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg 114 (2012), 275–285.
29. 29 Turbill, P., Beugeling, T., Poot, A.A., Proteins involved in the Vroman effect during exposure of human blood plasma to glass and polyethylene. Biomaterials 17 (1996), 1279–1287.
30. 30 Noble, S., Asgar, A., Cartier, R., et al. Anatomo-pathological analysis after CoreValve Revalving system implantation. EuroIntervention 5 (2009), 78–85.
31. 31 Luszczak, J., Undas, A., Gissel, M., et al. Activated factor XI and tissue factor in aortic stenosis: links with thrombin generation. Blood Coagul Fibrinolysis 22 (2011), 473–479.
32. 32 Seiler, C., Management and follow up of prosthetic heart valves. Heart 90 (2004), 818–824.
33. 33 Freudenberger, R.S., Hellkamp, A.S., Halperin, J.L., et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 115 (2007), 2637–2641.
34. 34 Mylotte, D., Andalib, A., Thériault-Lauzier, P., et al. Transcatheter heart valve failure: a systematic review. Eur Heart J 36 (2015), 1306–1327.
35. 35 Leiria, T.L., Lopes, R.D., Williams, J.B., et al. Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. J Thromb Thrombolysis 31 (2011), 514–522.
36. 36 Latib, A., Messika-Zeitoun, D., Maisano, F., et al. Reversible Edwards Sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol 61 (2013), 787–789.
37. 37 Pibarot, P., Dumesnil, J.G., Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation 119 (2009), 1034–1048.
38. 38 Stewart, W.J., Thrombosis of bioprosthetic valves: can we afford to ignore it?. J Am Coll Cardiol 66 (2015), 2295–2297.
39. 39 Barbetseas, J., Pitsavos, C., Aggeli, C., et al. Comparison of frequency of left atrial thrombus in patients with mechanical prosthetic cardiac valves and stroke versus transient ischemic attacks. Am J Cardiol 80 (1997), 526–528.
40. 40 Baddour, L.M., Wilson, W.R., Bayer, A.S., et al. American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 132 (2015), 1435–1486.
41. 41 Habets, J., Mali, W.P., Budde, R.P., Multidetector CT angiography in evaluation of prosthetic heart valve dysfunction. Radiographics 32 (2012), 1893–1905.
42. 42 Dangas, G.D., Giustino, G., Art and science of cerebrovascular event prevention after transcatheter aortic valve replacement. Circ Cardiovasc Interv, 9, 2016, e004307.
43. 43 Giustino, G., Dangas, G.D., Stroke prevention in valvular heart disease: from the procedure to long-term management. EuroIntervention 11:Suppl W (2015), W26–W31.
44. 44 Melgaard, L., Gorst-Rasmussen, A., Lane, D.A., et al. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 314 (2015), 1030–1038.
45. 45 Hamid, T., Choudhury, T.R., Anderson, S.G., et al. Does the CHA2DS2-Vasc score predict procedural and short-term outcomes in patients undergoing transcatheter aortic valve implantation?. Open Heart, 2, 2015, e000170.
46. 46 Mitchell, L.B., Southern, D.A., Galbraith, D., et al., APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart 100 (2014), 1524–1530.
47. 47 Pisters, R., Lane, D.A., Nieuwlaat, R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
48. 48 Fang, M.C., Go, A.S., Chang, Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 58 (2011), 395–401.
49. 49 Gage, B.F., Yan, Y., Milligan, P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151 (2006), 713–719.
50. 50 Kovacs, R.J., Flaker, G.C., Saxonhouse, S.J., et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol 65 (2015), 1340–1360.
51. 51 Brennan, J.M., Edwards, F.H., Zhao, Y., et al., DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 60 (2012), 971–977.
52. 52 Mérie, C., Køber, L., Skov Olsen, P., et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308 (2012), 2118–2125.
53. 53 Cheng, D., Pepper, J., Martin, J., et al. Stentless versus stented bioprosthetic aortic valves: a systematic review and meta-analysis of controlled trials. Innovations (Phila) 4 (2009), 61–73.
54. 54 Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al., RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013), 1206–1214.
55. 55 Jaffer, I.H., Fredenburgh, J.C., Hirsh, J., et al. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 13:Suppl 1 (2015), S72–S81.
56. 56 Yau, J.W., Stafford, A.R., Liao, P., et al. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 118 (2011), 6667–6674.
57. 57 Yau, J.W., Stafford, A.R., Liao, P., et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater 8 (2012), 4092–4100.
58. 58 Yau, J.W., Liao, P., Fredenburgh, J.C., et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123 (2014), 2102–2107.
59. 59 Jaffer, I.H., Stafford, A.R., Fredenburgh, J.C., et al. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc, 4, 2015, e002322.
60. 60 Dewanjee, M.K., Gross, D.R., Zhai, P., et al. Thrombogenicity of polyethylene oxide-bonded Dacron sewing ring in a mechanical heart valve. J Heart Valve Dis 8 (1999), 324–330.
61. 61 Yau, J.W., Liao, P., Fredenburgh, J.C., et al. Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. Thromb Haemost 112 (2014), 79–86.
62. 62 Greiten, L.E., McKellar, S.H., Rysavy, J., et al. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Eur J Cardiothorac Surg 45 (2014), 914–919.
63. 63 Webb, J., Rodés-Cabau, J., Fremes, S., et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol 28 (2012), 520–528.
64. 64 Van Mieghem, N.M., Schipper, M.E., Ladich, E., et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 127 (2013), 2194–2201.
65. 65 Hassell, M.E., Hildick-Smith, D., Durand, E., et al. Antiplatelet therapy following transcatheter aortic valve implantation. Heart 101 (2015), 1118–1125.
66. 66 Deeb, G.M., Reardon, M.J., Chetcuti, S., et al., CoreValve US Clinical Investigators. 3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 67 (2016), 2565–2574.
67. 67 Dangas, G.D., Lefevre, T., Kupatt, C., et al., BRAVO-3 Investigators. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial. J Am Coll Cardiol 66 (2015), 2860–2868.
68. 68 Van Belle, E., Hengstenberg, C., Lefevre, T., et al. Cerebral embolism during transcatheter aortic valve replacement: the BRAVO-3 MRI Study. J Am Coll Cardiol 68 (2016), 589–599.
69. 69 Windecker, S., Tijssen, J., Giustino, G., et al. Trial design: Rivaroxaban for the prevention of major cardiovascular events post transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J 184 (2017), 81–87.
70. 70 Assistance Publique - Hôpitaux de Paris. Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis (ATLANTIS). Available at: https://clinicaltrials.gov/ct2/show/NCT02664649. Accessed September 30, 2016.
71. 71 Cheung, A., Webb, J., Verheye, S., et al. Short-term results of transapical transcatheter mitral valve implantation for mitral regurgitation. J Am Coll Cardiol 64 (2014), 1814–1819.
72. 72 Anyanwu, A.C., Adams, D.H., Transcatheter mitral valve replacement: the next revolution?. J Am Coll Cardiol 64 (2014), 1820–1824.